Retrospective Analysis Results Positive for Talimogene in Melanoma

Share this content:
Retrospective Analysis Results Positive for Talimogene in Melanoma
Retrospective Analysis Results Positive for Talimogene in Melanoma

Amgen announced results from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and non-injected metastasized tumors.

The analysis included about 4,000 tumor lesions from a Phase 3 study that evaluated talimogene laherparepvec in patients with injectable unresected Stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). In the study, half of the lesions were injected with talimogene laherparepvec at least once, while the rest were non-injected, including visceral tumor lesions. Study results showed a >50% reduction in tumor size in 64% of injected tumors. In addition, 1/3 of non-injected non-visceral tumors, and 15% of visceral tumors were also reduced by >50%.

RELATED: Skin Cancer Resource Center

Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumor tissue and to initiate a systemic anti-tumor immune response. Talimogene laherparepvec is also designed to express GM-CSF, a white blood cell growth factor.

For more information call (800) 77-AMGEN or visit Amgen.com.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs